Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
799 Views
eMediNexus 11 January 2021
Treatment with dupilumab with concomitant topical corticosteroids led to rapid and sustained improvement in itch intensity and frequency in children 6-11 years of age with severe atopic dermatitis, revealed a post hoc analysis of a phase 3 trial LIBERTY AD PEDS (NCT03345914), presented at the Revolutionizing Atopic Dermatitis virtual symposium.
On the Peak Pruritus Numerical Rating Scale (NRS), treatment with dupilumab was found to be associated with a significant improvement from baseline in daily worst itch score through day 22 in the 300-mg q4w group and the 200-mg q2w group, compared with placebo (–29% vs. –30%, respectively; P less than or equal to .001 and P less than or equal to .05). Dupilumab treatment was also associated with a significant improvement from baseline in weekly average of daily worst itch score through week 16, compared with placebo (–55% vs. –58%; P less than or equal to .001). A higher daily proportion of dupilumab-treated patients attained a 2-point or more improvement in worst itch score, compared with placebo (51% vs. 49%; P less than or equal to .001 and P less than or equal to .05). The same association was noted for the daily proportion of dupilumab-treated patients attaining a 4-point or more improvement in worst itch score, compared with placebo (21% in both groups; P less than or equal to .05)… (Medscape)
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}